Objectives: Patients with LN have a poorer prognosis than patients without lupus nephritis (LN). Furthermore, class IV LN often has a poorer prognosis than other classes. In this study, we investigated the predictors for renal outcome after induction treatment in patients with class IV LN. Methods: All the enrolled adult patients were diagnosed with a renal biopsy-proven class IV LN in the Nephrology and Rheumatology Division between April 2015 and November 2020.  Biopsies were categorized according to ISN/RPS 2003 classification and were examined by light microscopy and direct immunofluorescence. All the enrolled patients receive induction treatment. Renal outcomes were evaluated by treatment responses classified as complete remission (CR), partial remission (PR), and treatment failure (TF) after induction treatment. 6 months was a median follow-up period after induction treatment. Results: This study enrolls 51 patients with lupus nephritis class IV (14 and 37 patients were diagnosed as IV-S subclass and IV-G subclasses, respectively). The baseline serum creatinine (Cr) level (mg/dL) was significantly lower in CR groups compare with PR and TF groups (0.8559 ± 0.4702 in CR, 1.0665 ± 0.5169 in PR, and 1.3511 ± 0.8721 in TF. p=0.034). There was no significant difference in age, sex, serum albumin, proteinuria and use of mycophenolate motefil (MMF) as an induction therapy among CR, PR and TF groups. Conclusions: Our data suggest that the baseline serum Cr level may be the predictor for renal outcome after induction therapy in patients with class IV LN. Future studies which enroll more numbers of patients with class IV LN were needed to find the novel predictors for renal outcome.